Sentynl Cares | NULIBRY Access and Support helps your child access NULIBRY

Fill out the enrollment form with your healthcare provider to register your child.

Sign up today

Download Enrollment Form

Sentynl Cares | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-251-2800

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

Continuing Support

Supporting you and your child doesn't stop when you have left the hospital and gone home. Sentynl Cares | NULIBRY is with you every step of the way. A trained member of the Sentynl Cares staff will contact you to assess any medication needs you may have. You will be contacted regularly to make sure things are going smoothly, and to ask about any questions that may have come up.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

SIDE EFFECTS

The most common side effects in NULIBRY-treated patients were infusion catheter–related complications, pyrexia (fever), viral infection, pneumonia, otitis media (ear infection), vomiting, cough/sneezing, viral upper respiratory infection (common cold/flu-like infection), gastroenteritis (stomach flu-like symptoms), diarrhea, and bacteremia (bacteria in the blood). Side effects for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.